Innovation potential in AI and viral pandemics

Today is the second day of the DRAGON consortium meeting. This was the first face to face meeting for DRAGON. That’s the reality when you have an project that was put together and funded as an emergency project to respond to the COVID-19 pandemic. Its been a clear reminder of the value of face to face interaction. What is great to see is that after the presentations yesterday followed by unstructured interactions through the evening it seems like the early career scientists and developers are more open about putting forth their ideas. That is an important development as they are often the ones with the best ideas.

Another feature of the DRAGON consortium is that a large number of the partners are SMEs. We have recently found out that three of the DRAGON emerging innovations have been selected for the Innovation Radar:

  1. Novel Data Harmonisation Techniques of Multicentre Information Fusion for COVID-19 Diagnosis and Prognosis - Imperial College London, University of Cambridge

  2. Federated learning system (DisTriM) - Radiomics

  3. Innovation Ecosystem for a learning healthcare system for viral pandemics - BioSci Consulting

The Innovation Radar is the European Commission’s internal database that identifies high potential innovations and innovators coming from EU-funded Research and Innovation projects.

Getting three innovations listed on the Innovation Radar speaks to the vibrance of the public/private collaboration that happens in DRAGON.

Following the face to face meetings there will be more effort to engage more of the external stakeholder community in accelerant projects that will take aim at the vision of creating a learning healthcare system that prepares us for the next pandemic.

Find out more about the DRAGON Stakeholder Community here. We are applying the BioPharmaX framework to transform the DRAGON consortium and stakeholder community into a translational ecosystem.

Previous
Previous

Reviews as value multipliers for collaborative innovation ventures

Next
Next

Engaging patient stakeholders early in the drug development process